NO20053087L - Pharmaceutical composition comprising an LTB4 antagonist and a COX-2 inhibitor or a combined COX 1/2 inhibitor. - Google Patents

Pharmaceutical composition comprising an LTB4 antagonist and a COX-2 inhibitor or a combined COX 1/2 inhibitor.

Info

Publication number
NO20053087L
NO20053087L NO20053087A NO20053087A NO20053087L NO 20053087 L NO20053087 L NO 20053087L NO 20053087 A NO20053087 A NO 20053087A NO 20053087 A NO20053087 A NO 20053087A NO 20053087 L NO20053087 L NO 20053087L
Authority
NO
Norway
Prior art keywords
inhibitor
cox
combined
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Application number
NO20053087A
Other languages
Norwegian (no)
Inventor
Franz Birke
Hans Michael Jennewein
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/012874 external-priority patent/WO2004047824A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20053087L publication Critical patent/NO20053087L/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår en farmasøytisk formulering omfattende en LTB4-antagonist som har en hydroksy- o g en benzamidin-gruppe eller en tautomer, et farmasøytisk akseptabelt salt eller solvat derav, spesielt en forbindelse med formel (I), hvor R og A er som definert i kravene, eller en tautomer, et farmasøytisk akseptabelt salt eller solvat derav (1) og minst én cyklooksygenase-2-inhibitor, en kombinert cox l/2-inhibitor eller et farmasøytisk akseptabelt salt eller solvat derav (2), og en farmasøytisk akseptabel bærer eller tilsetningsmiddel, og eventuelt én eller flere andre terapeutiske bestanddeler.The invention relates to a pharmaceutical formulation comprising an LTB4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt or solvate thereof, in particular a compound of formula (I) wherein R and A are as defined in the claims , or a tautomer, a pharmaceutically acceptable salt or solvate thereof (1) and at least one cyclooxygenase-2 inhibitor, a combined cox 1/2 inhibitor or a pharmaceutically acceptable salt or solvate thereof (2), and a pharmaceutically acceptable carrier or additive, and optionally one or more other therapeutic ingredients.

NO20053087A 2002-11-26 2005-06-23 Pharmaceutical composition comprising an LTB4 antagonist and a COX-2 inhibitor or a combined COX 1/2 inhibitor. NO20053087L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2622302A 2002-11-26 2002-11-26
PCT/EP2003/012874 WO2004047824A1 (en) 2002-11-26 2003-11-18 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor

Publications (1)

Publication Number Publication Date
NO20053087L true NO20053087L (en) 2005-06-23

Family

ID=35295281

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053087A NO20053087L (en) 2002-11-26 2005-06-23 Pharmaceutical composition comprising an LTB4 antagonist and a COX-2 inhibitor or a combined COX 1/2 inhibitor.

Country Status (1)

Country Link
NO (1) NO20053087L (en)

Similar Documents

Publication Publication Date Title
NO20070224L (en) 2-urea-4-phenylthiazole derivatives, preparation and therapeutic use thereof
TR200103186T2 (en) Quinoline derivatives as inhibitors of MEK enzymes
MX2009004475A (en) Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same.
DE602004008098D1 (en) SUBSTITUTED 2H-Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRAZINE AS GSK-3 INHIBITORS
NO20044731L (en) Quinoline and Isoquinoline Derivatives Process for Preparation thereof and its Use as Inflammatory Inhibitors
SE0202463D0 (en) Novel compounds
ECSP067076A (en) DERIVATIVES OF PIRIMIDINA UREA AS INHIBITORS OF QUINASA
SE0400284D0 (en) Novel compounds
NO20066055L (en) pyridine derivatives
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
NO20056192L (en) Capase inhibitors and their use
EA200500312A1 (en) NEW SPIROCONDENSED HINASOLINONES AND THEIR APPLICATION AS PHOSPHODYESTERES INHIBITORS
BR0309343A (en) Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions.
NO20072515L (en) 2-amido-4-phenyltnazole derivatives, preparation and therapeutic use thereof
ECSP045378A (en) NEW DIAZABICICLONONENE DERIVATIVES
TW200517106A (en) Sustained release pharmaceutical compositions
NO20080801L (en) Aerosol formulation for inhalation of beta agonists
BR0309342A (en) Compound, pharmaceutical composition, use of a compound, and method of treating or prophylaxis of human diseases or conditions.
SE0302192D0 (en) Novel compounds
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
NO20040881L (en) Oral antidiabetic agents.
ATE462703T1 (en) BICYCLONONE DERIVATIVES AS RENIN INHIBITORS
UA86776C2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0303480D0 (en) Benzofuranes
SE0301699D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application